Shots:

• The P-IIIb/IV PROPEL study involves assessing of Adynovate in prophylaxis targeting two different FVIII trough levels (1–3% REF/ 8–12% ELE) in prior treated patients with severe hemophilia A
• The P-IIIb/IV PROPEL study resulted in enhancing a patient’s PK profile by targeting ELE vs REF- patients with zero bleed (62% vs % vs 42%)- reduction in ABR (1.6 vs 3.6)- reduction in spontaneous joint ABR (0.5 vs 2.0) respectively
• Adynovate (Antihemophilic Factor (Recombinant)- PEGylated) is a factor replacement therapy and has received FDA’s approval followed by approval in Japan- Canada and is approved as Adynovi in Europe for the treatment & prophylaxis of bleeding in patients with hemophilia A aged ≥ 12yrs.

Click here to read full press release/ article

 Ref: Takeda | Image: Takeda